Lv31
350 积分 2025-01-07 加入
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group
6个月前
已完结
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
6个月前
已完结
CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia
6个月前
已完结
Long-Term Remissions of Severe Pemphigus After Rituximab Therapy Are Associated with Prolonged Failure of Desmoglein B Cell Response
7个月前
已完结
Comparing combination and single-agent therapy for the treatment of pemphigus: A retrospective cohort study
7个月前
已关闭
Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy
7个月前
已完结
Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab
7个月前
已完结
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
7个月前
已完结
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma
7个月前
已完结
Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial
7个月前
已完结
皖公网安备34019202002308
